Case Report
Cardiac Murmur in a Boy with Normal Paternal Prenatal Carrier Screening for Pompe Disease

Allison M. Jay,1 Premchand Anne,2 and David Stockton3

1Division of Genetics, Ascension St. John Hospital, Detroit, MI, USA
2Division of Pediatric Cardiology, Department of Pediatrics, Ascension St. John Children’s Hospital, Detroit, MI, USA
3Department of Genetics, Children’s Hospital of Michigan, Detroit, MI, USA

Correspondence should be addressed to Allison M. Jay; allyjcyprus@hotmail.com

Received 22 July 2019; Revised 13 November 2019; Accepted 25 November 2019; Published 12 December 2019

Academic Editor: Larry A. Rhodes

Copyright © 2019 Allison M. Jay et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Pompe disease is an autosomal recessive lysosomal storage disorder with marked morbidity and mortality, if untreated. With the advent of enzyme replacement therapy, it is essential to identify the infantile-type as early as possible to mitigate the effects of the enzyme deficiency. Identification is possible prenatally with testing of both parents. More recently, many states have instituted newborn screening for this condition. Case. We report a patient with infantile-onset Pompe disease with a normal paternal carrier genetic test, born prior to newborn screening for Pompe disease in the state of Michigan. The infant’s father was retested once the infant was diagnosed with Pompe disease postnatally and noted to have a mutation conducive to Pompe disease. Conclusion. Providers should have a strong clinical suspicion for disorders even if prenatal parental carrier screening is normal. A normal parental prenatal test does not exclude the possibility that the fetus may be diagnosed with a disorder postnatally, and pediatricians may be faced with limitations in accuracy of parents’ recollection of parental testing results.

1. Introduction
Pompe disease (OMIM 232300; glycogen storage type II; α-glucosidase deficiency) is an autosomal recessively inherited lysosomal storage disorder which occurs in approximately 1 in 40,000 infants. Infants typically present as “the floppy infant” with hypertrophic cardiomyopathy [1]. These infants with the classic type had a high mortality with death within the first year of life [2]. A later-onset form presents in childhood with skeletal muscle dysfunction and calf hypertrophy mirroring Duchene muscular dystrophy. Since 2006, enzyme replacement therapies have reduced the mortality and morbidity of this condition. Typically, patients will receive intravenous (IV) infusions every few weeks and have improved skeletal and cardiac function. Given a treatment that improved clinical outcomes, Pompe disease was added to the US Secretary of Health and Human Services on the Recommended Uniform Screening Panel in 2015 [3]. Through a blood spot sent in commonly in the newborn period, infants can now be detected if their state offers Pompe screening. Here we report an infant diagnosed with Pompe disease who was born two weeks prior to initiation of newborn screening (NBS) in the state of Michigan, who presented to his pediatrician at 4.5 months with a cardiac murmur. His parents had undergone an extensive prenatal screen and did not think Pompe disease was a likely diagnosis given the father’s reported normal result.

2. Case Report
A 4.5-month-old infant presented to his pediatrician for his 4-month well-child check. He was noted to have a 3/6 harsh, systolic ejection murmur along the left sternal border without radiation. He was subsequently referred for consultation to pediatric cardiology at our community hospital. The echo cardiogram (Figure 1) showed marked hypertrophy of the ventricle, and the electrocardiogram (ECG) indicated marked biventricular hypertrophy by voltage criteria. The infant also had mild, diffuse hypotonia. With the concern for Pompe disease, an α-glucosidase enzyme level was drawn. He was subsequently admitted to our
In conclusion, the symptoms of hypotonia, a cardiac murmur, and hypertrophic cardiomyopathy with marked intracavitary obstruction suggested the diagnosis of Pompe disease, which was subsequently confirmed by genetic testing. 

3. Discussion

Parental carrier testing in the prenatal setting is more expansive than ever, with many metabolic disorders screened. This patient’s case highlights that a normal result on a parental carrier screen does not exclude a diagnosis in a child. Patients should be counseled about the limitations of genetic technology, and understandably with the amount of conditions tested for they may not recall whether they were positive or negative for a specific condition. Pediatricians should also be aware of the limitations of current genetic technology; while in the past Sanger sequencing was used today, many current panels use next generation sequencing (NGS) for patient testing [4]. This method allows for the generation of massive amounts of data from an individual patient through sequencing millions of fragments in a parallel manner. Pediatricians should be aware that read depth and coverage, which indicate how well a region of the gene is interrogated, may vary from lab to lab and may be a source of error in patient testing if this is inadequate. Coverage of GC rich regions and areas of high homology to other regions in the genome, for instance, is always challenging. In addition, some laboratories only offer targeted testing of certain mutations, so while a negative result may indicate the absence of any of the targeted mutations, this does not exclude the possibility entirely of another mutation elsewhere in the gene. Finally, there is the possibility of gonadal mosaicism in which a parental carrier screen on peripheral blood would not identify a mutation.

Pediatricians are often on the front lines taking histories and gathering information on prenatal history and may be faced with limited recollections as well as with parents who bring extensive paperwork with their prenatal carrier screens. Pediatricians may be asked to interpret these parental reports and apply them to the child before them. It is prudent to look at positive findings from such reports and take that into the clinical differential if a patient is having symptoms, and also equally important not dismiss a potential diagnosis based on a parent’s recollection their screening was normal. While our patient received genetic counseling over the phone, the patient’s parents still believed that Pompe could not be the cause of their child’s condition given a negative result on the father’s prenatal screen.

In conclusion, the symptoms of hypotonia, a cardiac murmur, and hypertrophic cardiomyopathy with marked intracavitary obstruction suggested the diagnosis of Pompe disease, which was subsequently confirmed by genetic testing. Astute clinical judgement is needed in cases where molecular testing is inconsistent and strong clinical suspicion may be needed for the infant presenting with cardiac and noncardiac signs and symptoms. There may be
limitations with the genetic technology a patient has had performed which cause a mutation to be missed as has been reported in one case with Pompe by Tsai et al. [5]. In such cases, biochemical testing may be warranted to further evaluate these patients through checking enzymatic activity. With the addition of Pompe disease to the newborn screening in many states, this will allow for the earlier detection of this condition; however, there are numerous other biochemical disorders that may affect patients presenting to pediatrician. It is prudent to review the prenatal results and evaluate the need for additional workup if patients’ symptoms are concerning for a metabolic condition. Parents may not recall what their parental carrier testing results were accurately; it is important for the physician to confirm the results with an official report, and to be cognizant that a normal result does not exclude a diagnosis.

**Conflicts of Interest**

Dr. Allison Jay and Dr. Premchand Anne have no conflicts of interest. Dr. David Stockton receives research funding, consulting, and speaker fees from Sanofi Genzyme.

**Acknowledgments**

The authors would like to thank Dr. Linda Hasadsri and Dr. Erin Wakeling for their careful and thoughtful insights on the manuscript, and Justin Beatty for his thorough review of the references. In addition, the authors would like to thank the patient and his family for their contribution to educate pediatricians and health care professionals to give better care to children with genetic diseases.

**References**

[1] S. Tortorelli, J. S. Eckerman, J. J. Orsini et al., “Moonlighting newborn screening markers: the incidental discovery of a second-tier test for Pompe disease,” *Genetics in Medicine*, vol. 20, no. 8, pp. 840–846, 2018.

[2] ACMG Work Group on Management of Pompe Disease, P. S. Kishnani, R. D. Steiner et al., “Pompe disease diagnosis and management guideline,” *Genetics in Medicine*, vol. 8, no. 5, pp. 267–288, 2006.

[3] S. Burwell, “Secretary’s Final Response RE Committee’s recommendation to add Pompe disease to the RUSP,” 2015, https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/reports-recommendations/secretary-final-response-pompe.pdf.

[4] K. Komlosi, A. Sólyom, and M. Beck, “The role of next-generation sequencing in the diagnosis of lysosomal storage disorders,” *Journal of Inborn Errors of Metabolism and Screening*, vol. 4, 2016.

[5] A. C.-H. Tsai, Y.-W. Hung, C. Harding, D. M. Koeller, J. Wang, and L.-J. C. Wong, ”Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease,” *American Journal of Medical Genetics Part A*, vol. 173, no. 9, pp. 2500–2504, 2017.